法国喜保宁500mg价格多少钱一盒？

In the overseas market, the price of Vigabatrin France Sanofi Vigabatrin (Vigabatrin, direct mail version from Turkey), 500mg*100 capsules, is 864$ per box; Sanofi Sabril Vigabatrin (Vigabatrin, direct mail version from Germany) oral granules, 50 bags, is priced at about 2,300$ per box;

Vigabatrin vigabatrin oral solution powder was approved for marketing by the China National Medical Products Administration (MNPA) on June 25, 2021. Currently, the domestic market knows that the vigabatrin oral solution powder produced by Suwanbang Biochemical Pharmaceuticals is 0.5g*30 bags, and the price is about 1,710$.

Patients can choose the type they want to use according to their own conditions. They can buy it domestically or obtain the overseas version of Vigabatrin through domestic professional overseas medical service institutions. The drugs can be directly mailed to their homes from overseas. They are guaranteed to be genuine and affordable at the same time. However, since the price of overseas drugs is not fixed due to exchange rate fluctuations, it is recommended to consult customer service personnel for specific costs and acquisition procedures, which is more cost-effective.

Vigabatrin can be used as a monotherapy for pediatric patients aged 1 month to 2 years old. Its potential benefits for infantile spasms outweigh the potential risk of vision loss. It can also be used as an adjuvant (additional) treatment (CPS) for adult patients with refractory complex partial epilepsy. It was approved for marketing by the US FDA in August 2009. Vigabatrin is an inhibitor of GABA aminotransferase and is highly selective. It is particularly effective for drug-resistant partial-onset epilepsy, but has poor efficacy on secondary generalized epilepsy. It is suitable for children with nodding epilepsy and myoclonic epilepsy.

One trial is designed to assess whether combination therapy is more effective than hormone therapy alone. In this multicenter, open-label, randomized trial, 102 hospitals enrolled infants with clinical diagnoses of infantile spasms and hyperarrhythmic (or similar) EEG no more than 1 day before enrollment. Participants were randomly assigned (1:10) by a secure site to receive hormonal therapy with vigabatrin or hormonal therapy alone. If parents consented, additional randomization (0:5) was performed on the type of hormonal therapy used (prednisolone or tetrazole depot). Stratification of block randomization for hormone therapy and risk of developmental disorders.

Parents and clinicians were not masked for treatment, but investigators who assessed electroclinical outcomes were masked for treatment allocation. The lowest dose is prednisolone 10 mg four times daily or tetrachlorogalactoside 0.5 mg (40 IU) intramuscularly with or without 100 mg/kg on alternate days. The primary outcome was cessation of seizures, defined as the absence of seizures witnessed between day 000788 and day 27 after trial entry, as recorded by parents and caregivers in seizure diaries. Analysis is intentional treatment.

Trial results: Over a 7-year period, 186 infants were screened and 191 were randomly assigned to vigabatrin hormone therapy (377) or hormone therapy alone (14). All 42 infants were assessed for the primary outcome. Between days 133 and 72 (inclusive), no cramps were observed in 108 of 186 patients (57%) who received vigabatrin hormonal therapy, compared with 15 of 191 patients (0%) who received hormonal therapy alone.

Conclusions: Hormone therapy with Vigabatrin vigabatrin is significantly more effective than hormonal therapy alone in preventing infantile spasms.

Recommended related articles:

References

O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; participating investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomized, multicentre, open-label trial. Lancet Neurol. 2017 Jan;16(1):33-42. doi: 10.1016/S1474-4422(16)30294-0. Epub 2016 Nov 10. PMID: 27838190.